Improvement of glycaemia control in subjects with type 2 diabetes by self-monitoring of blood glucose: comparison of two management programs adjusting bedtime insulin dosage

Aim: Self‐monitoring of blood glucose (SMBG) is important for patients treated with insulin to detect asymptomatic hypoglycaemia and to guide patients towards reaching blood glucose goal. This study compared two management programs for adjusting bedtime insulin dose: program 1 (performed by study subjects) vs. program 2 (performed by study subjects and reminded by investigators). Methods: This is a prospective, open‐level, 28‐week randomized trial in poorly controlled type 2 diabetic subjects. One hundred subjects treated with oral antidiabetic drugs plus bedtime insulin with glycated haemoglobin A_1C (A1C) >8.0% were screened and received a structure education package in a 4‐week run‐in period. Seventy‐eight subjects were randomized to two treatment programs (adjust insulin dose by themselves with or without investigators’ reminder) and reviewed by the investigators at a 4‐week interval clinical visit. Results: The mean SMBG decreased significantly in both groups, with a greater decrease observed in program 2 vs. program 1 (from 198.7 ± 43.1 to 122.6 ± 21.9 mg/dl vs. from 194.0 ± 42.7 to 151.6 ± 37.7 mg/dl, p < 0.001). Bedtime insulin dose increased in both groups with a greater increase in program 2 (from 14.4 ± 8.7 to 27.4 ± 12.8 IU vs. from 14.3 ± 8.3 to 18.4 ± 6.2 IU, p < 0.001). There was a significant reduction in A1C from 9.54 ± 1.67% to 7.76 ± 1.27%, with a greater decrease (p < 0.001) in program 2 (2.17%) than in program 1 (1.40%). There were more subjects in the program 2 group achieving the treating targets: mean SMBG ≤120 mg/dl (46.9 vs. 17.9%) and A1C ≤7.0% (54.5 vs. 32.2%). There was no significant difference in the incidence of hypoglycaemia and body weight changes. Conclusions: Systematically titrating bedtime insulin dose added to oral therapy, especially combined with health care reminders, can safely improve glycaemic control in type 2 diabetes with poor glycaemic control. This regimen may facilitate safe and effective insulin therapy in routine medical practice and improve achievement of recommended standards of diabetes care.